Search results
Results from the WOW.Com Content Network
Merck & Co. traces its origins to its former German parent company Merck Group, which was established by the Merck family in 1668 when Friedrich Jacob Merck purchased a drug store in Darmstadt. [ 27 ] [ 28 ] In 1827, Merck Group evolved from a pharmacy to a drug manufacturer company with the commercial manufacture of morphine . [ 29 ]
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare ...
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co. Inc. (MRK), CVS Health Corporation (CVS), and American Tower Corporation (AMT).
Sigma-Aldrich was created in 1975 by the merger of Sigma Chemical Company and Aldrich Chemical Company. It grew through various acquisitions until it had over 9,600 employees and was listed on the Fortune 1000. The company has two United States headquarters, in St. Louis and Burlington, MA and has operations in approximately 40 countries. [7]
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive third-quarter sales. However, genericization of key drugs and increasing competition are concerns.